| Literature DB >> 27220357 |
Bronwen Connolly1, Brenda O'Neill2, Lisa Salisbury3, Bronagh Blackwood4.
Abstract
BACKGROUND: Physical rehabilitation interventions aim to ameliorate the effects of critical illness-associated muscle dysfunction in survivors. We conducted an overview of systematic reviews (SR) evaluating the effect of these interventions across the continuum of recovery.Entities:
Keywords: Exercise
Mesh:
Year: 2016 PMID: 27220357 PMCID: PMC5036250 DOI: 10.1136/thoraxjnl-2015-208273
Source DB: PubMed Journal: Thorax ISSN: 0040-6376 Impact factor: 9.139
Figure 1Flow diagram summarising systematic review selection. OLS, online supplementary material; RCT, randomised controlled trial.
Characteristics of included systematic reviews
| Author (year) | Stage of recovery continuum | Search dates* | Population† | Intervention | Comparator | Category of outcome | Quality appraisal method |
|---|---|---|---|---|---|---|---|
| Kayambu | In ICU | 1980 to January 2012 | Patients receiving physical therapy in the ICU | Physical therapy | No or minimal physical therapy in contrast to the intervention group | Peripheral muscle strength Respiratory muscle strength ICU and hospital LOS Mortality | PEDro |
| Hermans | In ICU | 1966 to 4 October 2011 | Adult (≥18 years of age) admitted to a medical, surgical or mixed ICU | Physiotherapy | Placebo, no treatment or a different treatment | Duration of MV ICU LOS 30d and 180d mortality | Cochrane Risk of Bias |
| Wageck | In ICU | Up until 26 November 2013 | Adult (≥18 years of age) critically ill patients in the ICU for ≥48 hours | NMES | Not specified | Muscle strength Muscle structure ICU LOS Duration MV | PEDro |
| Calvo-Ayala | Across all stages | January 1990 to December 2012 | Exercise/physical therapy | Placebo, no treatment or a different treatment | PEDro | ||
| Connolly | Post-ICU discharge | 1966 to 15 May 2014 | Exercise rehabilitation or training | Any other intervention, control or ‘usual care’ programme | Cochrane Risk of Bias |
*Search dates reported as per individual systematic review and may/may not include specific detail.
†Population described as per individual systematic review and may/may not include specific ‘Inclusion’ and ‘Exclusion’ criteria.
‡SR includes any treatment related to decreasing risk of CIP/CIM; data reported relate to physical rehabilitation interventions included.
§SR includes any treatment where long-term PF was an outcome; data reported relate to physical rehabilitation interventions included.
¶NB include ‘Other’ outcomes related to trial intervention, for example, withdrawal rates, adherence and loss to follow-up.
AMSTAR, Assessment of Multiple Systematic Reviews; CIM, critical illness myopathy; CIP, critical illness polyneuropathy; EMS, electrical muscle stimulation; ICU, intensive care unit; LOS, length of stay; MV, mechanical ventilation; NMES, neuromuscular electrical stimulation; PEDro, Physiotherapy Evidence Database; PF, physical function.
Results for PRISMA and AMSTAR quality appraisal of included systematic reviews
| Author | PRISMA score (/27) | PRISMA score (% of applicable) | AMSTAR score (/11) | AMSTAR score (% of applicable) | AMSTAR quality grade |
|---|---|---|---|---|---|
| Kayambu | 17 | 68.0 | 6 | 54.5 | Medium |
| Hermans | 25 | 96.2 | 10 | 90.9 | High |
| Wageck | 17 | 70.8 | 6.5 | 54.5 | Medium |
| Calvo-Ayala | 16 | 69.6 | 7 | 70.0 | Medium |
| Connolly | 25 | 100 | 8 | 88.9 | High |
| Summary | 17.0 (16.5–25.0) | 70.8 (68.8–98.1) | 7.0 (6.3–9.0) | 70.0 (54.5–89.9) | – |
Figure 2Summary of PRISMA checklist section items reported across all included reviews. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.
Figure 3Summary of completion of AMSTAR items across all included reviews. For full AMSTAR item descriptors, see online supplementary section E5. AMSTAR, Assessment of Multiple Systematic Reviews.
Summary of findings: intervention: physical rehabilitation; comparison: usual care
| WHO domain outcome | Review author; N studies: N patients | Pooled effect (95% CI) | GRADE of evidence | Explanation |
|---|---|---|---|---|
| Peripheral muscle strength | Kayambu | Hedge's g=0.27 (0.02 to 0.52), p=0.03 | ϴϴ | Downgraded −2 for serious risk of bias and imprecision |
| Respiratory muscle strength | Kayambu | Hedge's g=0.51 (0.12 to 0.89), p=0.01 | ϴϴ | Downgraded −2 for serious risk of bias and imprecision |
| CIP/CIM | Hermans | RR 0.62 (0.39 to 0.96) p=0.03 | ϴϴϴϴ | |
| Physical function‡ | Kayambu | Hedge's g=0.46 (0.13 to 0.78), p=0.01 | ϴϴ | Downgraded −2 for serious risk of bias and imprecision |
| Quality of Life | Kayambu | Hedge's g=0.40 (0.08 to 0.71), p=0.01 | ϴϴϴϴ | |
| VFD | Kayambu | Hedge's g=0.38 (0.16 to 0.59), p<0.001 | ϴϴϴ | Downgraded −1 for imprecision |
| ICU LOS | Kayambu | Hedge's g=−0.34 (−0.51 to −0.18), p<0.001 | ϴϴϴϴ | |
| Hospital LOS | Kayambu | Hedge's g=−0.34 (−0.53 to −0.15), p<0.001 | ϴϴϴϴ | |
| Hospital mortality | Kayambu | OR 1.0. (0.54 to 1.85) p=1.0 | ϴϴϴϴ | |
| Duration of MV | Hermans | Median (IQR) 3.4 days (2.3 to 7.3) vs 6.1 days (4.0 to 9.6), p not reported | ϴϴϴ | Downgraded −1 for inadequate reporting of effect |
Stage of recovery: in the ICU.
*50% no random allocation; 50% no concealed allocation; 50% no blinded assessors; 50% not reported measures of key outcomes >85% patients and outcome was measured at different end points.
†50% no concealed allocation; 50% no blinded assessors; 50% not reported measures of key outcomes >85% patients; 100% no ITT and unclear end point in one study.
‡Data from Kayambu et al,26 no pooled data reported in Calvo-Ayala et al.24
§50% no allocation concealment; 50% not reported measures of key outcomes >85% patients; 50% no ITT and outcome was measured at different end points.
¶Measured at different end points.
**Outcome from same RCT reported in both reviews.
††Inadequate reporting of effect.
CIP/CIM, critical illness polyneuropathy/myopathy; ICU, intensive care unit; ITT, intention to treat; LOS, length of stay; MV, mechanical ventilation; RCT, randomised controlled trials; RR, risk ratio; VFD, ventilator-free days.
Summary of findings; intervention: NMES
| WHO domain outcome | Review author; | Pooled effect (95% CI) | GRADE of evidence | Explanation |
|---|---|---|---|---|
| Muscle strength | Wageck | SMD 0.77, (0.13 to 1.40), p=0.02 | ϴ | Downgraded −3 for serious risk of bias, inconsistency and imprecision |
| Muscle structure | Wageck | Not possible to pool | ϴϴ | Downgraded −2 for serious inconsistency and indirectness |
| CIP/CIM | Hermans | RR 0.32 (0.10 to 1.01), p=0.05 | ϴϴ | Downgraded −2 for serious risk of bias and indirectness |
Comparison: usual care. Stage of recovery: in the ICU.
*50% no concealed allocation; 50% no blinded assessors; 50% not reported measures of key outcomes >85% patients; 50% no ITT and mean difference in one study does not fall within the 95% CI of the other.
†Three studies reported an effect and three did not; and different outcome measures were used at different timepoints.
‡High ROB reported by review for this study vis-à-vis randomisation, concealment, incomplete outcome data and selective reporting; and not all participants were evaluable.CIP/CIM, critical illness polyneuropathy/myopathy; ICU, intensive care unit; ITT, intention to treat; NMES, neuromuscular electrical stimulation; ROB, risk of bias; RR, risk ratio; SMD, standard mean difference.
Summary of findings; intervention: physical rehabilitation
| WHO domain outcome | Review author; N studies: N patients | Pooled effect (95% CI) | GRADE of evidence | Explanation |
|---|---|---|---|---|
| Functional exercise capacity | Connolly | Unable to pool data due to variability in use of outcome measures across individual studies | ϴ | Downgraded −3 due to variability in multiple aspects of methodology across studies, risk of bias and differences in data reporting |
| Health-related quality of Life | Connolly | Unable to pool data due to variability in use of outcome measures across individual studies and small study number | ϴ | Downgraded −3 due to variability in multiple aspects of methodology across studies, risk of bias and differences in data reporting |
| Mortality | Connolly | Unable to pool data due to variation in study design; no deaths reported in two studies; no difference in mortality rates between intervention and control groups in remaining four studies | ϴϴ | Downgraded −2 due to serious inconsistency and imprecision |
| Non-mortality adverse events | Connolly | Three studies reported no adverse events; one study reported no significant difference between groups for adverse events (n=1 event only) | ϴϴ | Downgraded −2 due to lack of reported data from two studies and serious imprecision |
Comparison: usual care. Stage of recovery: post-ICU discharge. *Data reported are overall number of participants enrolled in each study. Multiple outcome measures were observed across studies with variable numbers of patients for each measure according to each study.
ICU, intensive care unit.
Recommendations and rationale for future research
| Recommendation | Rationale |
|---|---|
| The current evidence for these specific areas is currently low and/or insufficient. Focusing on these topics would address gaps in the existing evidence base | |
| Stratification of patient cohorts that would benefit from rehabilitation interventions would streamline the rehabilitation pathway, greater efficiency of resource utilisation and cost-effectiveness as well as delivering personalised care | |
| Increase transparency of intervention delivered within the trial, improve reporting of interventions in a systematic and structured manner, enhance interpretation of findings | |
| Facilitate understanding of the clinical context in which the intervention was trialled, and assist in interpretation of findings and determining generalisability | |
| COS facilitate greater comparison across studies, pooling of datasets for meta-analyses and clinical applicability of results. Patient-reported outcomes were not evident from the current overview, and long-term follow-up was limited. Adverse event rates are valuable for considering clinical efficacy of an intervention even if statistically significant differences are observed | |
| Ensure trial findings are reported in context of most current existing data | |
| Publication of a priori trial protocol developed in line with Standard Protocol Items: Recommendations for Interventional Trials guidance | Enhances credibility of final publication of trial findings by supplementing clinical trial registration; streamlines final publication text; comprehensive reporting of key trial components facilitates transparency |
| Include a process evaluation framework into trial design of complex interventions | To distinguish true intervention effect from factors related to delivery of intervention and trial conduct; explain contextual influences and provide insight into wider implementation |
COS, core outcome sets; ICU, intensive care unit; NMES, neuromuscular electrical stimulation.